Dr. Yendry Ventura oversees Abu Dhabi Stem Cells Center operations as its Chief Executive Officer. ADSCC is the first fully integrated medical and research center focused on attaining the most leading and ambitious scopes in the fields of cell therapy in the UAE. A skilled scientific researcher in preforming, conducting, and analyzing in vivo and in vitro assays, as well as preclinical studies related to cell biology, immunology, cancer, and autoimmune diseases.
Dr. Yendry has developed new innovative methodology for harvesting stem cells through peripheral blood, this methodology was used in a clinical trial of COVID-19 patients and is known as UAECell-19 with Abu Dhabi Stem Cells Center as its sole owner. He is also the executive director of the first bone marrow transplantation program in the UAE, known as AD-BMT. AD-BMT has intellectual property and is a comprehensive program designed to treat every patient in the UAE that may be eligible for the treatment.
Dr Yendry Ventura implemented the very first CAR-T cells and Extracorporeal Photopheresis program. He is the Chairman of the Pharmacogenomics Flagship Program of Abu Dhabi Stem Cells Center and the Principal Investigator of the randomized controlled clinical trials for Multiple Sclerosis, Type 1 Diabetes Mellitus and others.
Dr. Yendry holds a Doctorate in Medicine in Immunology from the University of Havana- Cuba.
He brings a wealth of leadership and clinical expertise, including performance in clinical sciences, managing clinical research and leading clinical trials. He has extensive knowledge in stem cell harvesting and isolation, using these techniques in the implementation of therapeutic and productive apheresis methods used in hematopoietic stem cells transplantations, as well as obtaining autologous stem cells for regenerative medicine. Dr. Yendry’s primary field of interest is in preclinical and clinical research such as clinical trials and compassionate protocols.